University Hospital Zurich, Research and Education Office
https://www.usz.ch/forschung/Seiten/default.aspx
8091 Zürich, Rämistrasse 100
The University Hospital Zurich is one of Switzerland’s largest hospitals and a pioneering institution in the field of clinical research. In its 40 departments and institutes, it assembles and practices all medical disciplines and enjoys an excellent reputation for state-of-the-art medicine, professional and com- passionate patient care, and groundbreaking bench-to-bedside translational medical research.
University Hospital Zurich, Research and Education Office
Rämistrasse 100
8091 Zürich
211 Ergebnisse für "immunotherapy com com" unter University Hospital Zurich, Research and Education Office
The updated Swiss guidelines 2016 for the treatment and follow-up o...
... subtypes [6] Superficial spreading melanoma (SSM) is the most com- mon subtype (70%) and is characterised ... of treatments, whether with small molecules or immunotherapy, one of the most important challenges ... subtypes [6] Superficial spreading melanoma (SSM) is the most com- mon subtype (70%) and is characterised ... of treatments, whether with small molecules or immunotherapy, one of the most important challenges ...
University of Zurich
https://www.campus-schlieren.uzh.ch/en.html
8952 Schlieren, Wagistrasse 12
The University of Zurich (UZH) is Switzerland’s largest university, with seven faculties and a current enrollment of over 26,000 students. More than 5,000 highly qualified members of the teaching staff, including some 580 professors, teach and conduct research at the 150 University institutes. In the field of life sciences, the University of Zurich is well known for its groundbreaking research in medicine, immunology, neuroscience, and structural biology. In the interest of serving the community, the University of Zurich promotes the transfer of research-based knowledge to private enterprise, and our spin-off ventures and business partnerships regularly lead to the creation of attractive jobs in innovative fields.
University of Zurich
Wagistrasse 12
8952 Schlieren
826 Ergebnisse für "immunotherapy com com" unter University of Zurich
UZH - UFSP Dynamik Gesunden Alterns - Dipl. rer. com. Susanne Nieke
... Susanne Nieke, Dipl. rer. com. Wissenschaftliche Mitarbeiterin ... UZH - UFSP Dynamik Gesunden Alterns - Dipl. rer. com. Susanne Nieke ... UZH - UFSP Dynamik Gesunden Alterns - Dipl. rer. com. Susanne Nieke Home Hauptnavigation Suche ... UZH - UFSP Dynamik Gesunden Alterns - Dipl. rer. com. Susanne Nieke ...
UZH - URPP Dynamics of Healthy Aging - Dipl. rer. com. Susanne Nieke
... Susanne Nieke, Dipl. rer. com. Wissenschaftliche Mitarbeiterin ... UZH - URPP Dynamics of Healthy Aging - Dipl. rer. com. Susanne Nieke ... UZH - URPP Dynamics of Healthy Aging - Dipl. rer. com. Susanne Nieke Home Main navigation Search ... UZH - URPP Dynamics of Healthy Aging - Dipl. rer. com. Susanne Nieke ...
ETH Entrepreneurship
https://ethz.ch/en/industry/entrepreneurship.html
8952 Schlieren, Wagistrasse 18
Excellence in entrepreneurship at ETH Zurich is driven by world-class research and education. It gives rise to groundbreaking new ventures that consolidate Switzerland’s technological leadership. Are you an aspiring entrepreneur seeking to find solutions to global challenges and create a better future for humanity. Or are you just interested in the entrepreneurial ecosystem at ETH Zurich? Browse our websites to find out more or reach out to the Entrepreneurship group, if you have any questions.
ETH Entrepreneurship
Wagistrasse 18
8952 Schlieren
1504 Ergebnisse für "immunotherapy com com" unter ETH Entrepreneurship
Consequences of pseudo-participatory approaches towards post-disast...
... com ... com ...
Consequences of pseudo-participatory approaches towards post-disast...
... com ... com ...
Somagenetix
https://www.wysszurich.ch/projects/somagenetix
8952 Schlieren, Wagistrasse 23
Gene therapy solutions for patients with severe inherited diseases.
Somagenetix
Wagistrasse 23
8952 Schlieren
900 Ergebnisse für "immunotherapy com com" unter Somagenetix
Entrevista com João Adolfo Hansen por Eduardo Jorge de Oliveira, Jú...
... Entrevista com João Adolfo Hansen por Eduardo Jorge de Oliveira, Júlia de Carvalho Hansen e Marcela ... professor que, através do turno da noite lidou com a realidade brasileira de textos, dentre outros, os de ... Entrevista com João Adolfo Hansen por Eduardo Jorge de Oliveira, Júlia de Carvalho Hansen e Marcela ... Entrevista com João Adolfo Hansen por Eduardo Jorge de Oliveira, Júlia de Carvalho Hansen e Marcela ... Entrevista com João Adolfo Hansen por Eduardo Jorge de Oliveira, Júlia de Carvalho Hansen e Marcela ...
Entrevista com Raúl Antelo por Eduardo Jorge de Oliveira, Eduardo S...
... de Oliveira, Eduardo Jorge ; Sterzi, Eduardo ; Stigger, Verônica (2020). Entrevista com Raúl Antelo ... seminário Museus e materialidades da literatura. Com trânsito livre entre Brasil e Argentina, ou melhor, com ... Entrevista com Raúl Antelo por Eduardo Jorge de Oliveira, Eduardo Sterzi e Verônica Stigger ... Entrevista com Raúl Antelo por Eduardo Jorge de Oliveira, Eduardo Sterzi e Verônica Stigger ... Entrevista com Raúl Antelo por Eduardo Jorge de Oliveira, Eduardo Sterzi e Verônica Stigger ...
CUTISS AG
8952 Schlieren, Grabenstrasse 11
+41 44 244 36 60
info@cutiss.swiss
After more than 15 years of research (Tissue Biology Research Unit, University Children’s Hospital Zurich), CUTISS AG can now bio-engineer large quantities of individually customized human skin grafts, denovoSkin™, starting off from a very small piece of healthy patient’s skin. Because of its intrinsic characteristics, denovoSkin™ is expected to result in a minimally scarring outcome after transplantation. denovoSkin™ received a Swissmedic, EMA and FDA Orphan drug designation for the treatment of burns.
CUTISS AG
Grabenstrasse 11
8952 Schlieren
5 Ergebnisse für "immunotherapy com com" unter CUTISS AG
Fallstudie: denovoSkin™ in der rekonstruktiven pädiatrischen Verbre...
... Com ... Com ...
Roche Glycart AG
https://www.roche.ch/en/sites/schlieren
8952 Schlieren, Wagistrasse 10
+41 43 215 10 00
The mission of the Roche Innovation Center Zurich (RICZ) is to be a leader in developing new generations of engineered antibody products with increased efficacy that address unmet clinical needs. The RICZ site is also the Center of Excellence in Cancer Immunotherapy within the Roche Group.
Roche Glycart AG
Wagistrasse 10
8952 Schlieren
227 Ergebnisse für "immunotherapy com com" unter Roche Glycart AG
Roche - Immunotherapy at Roche
... Neuroscience Our approach to cancer immunotherapy Some people can point to a book that changed ... Immunotherapy Development at Roche. For decades, researchers trying to devise new treatments for cancer have ... Roche - Immunotherapy at Roche ... https://www.roche.com/research_and_development/what_we_are_working_on/oncology/cancer- immunotherapy ... Roche - Immunotherapy at Roche ...
Roche - Discover Roche’s latest innovations in cancer immunotherapy
... & Development You are here: Meet the scientists exploring new immunotherapy pathways in the battle against ... words, cancer immunotherapy aims to harness the power of the immune system to fight cancer. Like brakes ... Roche - Discover Roche’s latest innovations in cancer immunotherapy ... https://www.roche.com/research_and_development/what_we_are_working_on/oncology/cancer- immunotherapy ... Roche - Discover Roche’s latest innovations in cancer immunotherapy ...
ImmunOs Therapeutics AG
http://immunostherapeutics.com/
8952 Schlieren, Wagistrasse 14
ImmunOs Therapeutics AG is a clinical-stage biotechnology company developing the next generation of novel immunotherapies that enhance the efficacy of market leading checkpoint inhibitors and costimulatory agonists for cancer therapy. The company is actively discussing and exploring new strategic collaborations with leading global pharmaceutical companies.
ImmunOs Therapeutics AG
Wagistrasse 14
8952 Schlieren
21 Ergebnisse für "immunotherapy com com" unter ImmunOs Therapeutics AG
Background on Cancer Immunotherapy - Immunostherapy
... Contact Background on Cancer Immunotherapy Current approaches in cancer immunotherapy focus mainly ... prevent T cells from eliminating cancer cells (checkpoint inhibitors). Cancer immunotherapy has been a ... Background on Cancer Immunotherapy - Immunostherapy ... https://www.immunostherapeutics.com/approach/background-on-cancer- immunotherapy/ ... Background on Cancer Immunotherapy - Immunostherapy ...
Investors | Immunos Therapeutics
... private investors. The Company has built a preclinical portfolio of novel immunotherapy candidates and is ... Company has built a preclinical portfolio of novel immunotherapy candidates and is currently exploring ...
Virometix AG
8952 Schlieren, Wagistrasse 14
+41 (0)43 433 86 60
info@virometix.com
Virometix AG is a privately held biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and chronic human diseases.
Virometix AG
Wagistrasse 14
8952 Schlieren
5 Ergebnisse für "immunotherapy com com" unter Virometix AG
Newsroom - Virometix AG
... Research Collaboration to Use Synthetic Virus-Like Particles for Ultra-Fast Allergy Immunotherapy Study is ... immunotherapy, and Virometix AG, a company developing a new generation of vaccines and immunotherapeutic drugs ... August – 02 September 2022; https://www.eps2022. com/ ). With presentations on our T-cell epitope SARS-CoV ... Announce Research Collaboration to Use Synthetic Virus-Like Particles for Ultra-Fast Allergy Immunotherapy ...
Microsoft Word - 200709 Joint PR Anergis_Virometix_HZI_final_approv...
... Allergy Immunotherapy - Study is performed at the Helmholtz Centre for Infection Research and supported by ... Contiguous Overlapping Peptides (COPs) for ultra-fast allergy immunotherapy, and Virometix AG, a company ... Allergy Immunotherapy - Study is performed at the Helmholtz Centre for Infection Research and supported by ... Contiguous Overlapping Peptides (COPs) for ultra-fast allergy immunotherapy, and Virometix AG, a company ...
Neurimmune Therapeutics AG
8952 Schlieren, Wagistrasse 18
+41 44 755 46 46
info@neurimmune.com
Neurimmune is a biopharmaceutical company dedicated to the development of immunotherapeutics for the treatment and prevention of human disorders with a focus on protein aggregation diseases.
Neurimmune Therapeutics AG
Wagistrasse 18
8952 Schlieren
10 Ergebnisse für "immunotherapy com com" unter Neurimmune Therapeutics AG
Neurimmune - Lab Insights: Immunotherapy for Type-2 diabetes
... All News and Press Releases Lab Insights: Immunotherapy for Type-2 diabetes Neurimmune is pursuing ... the development of an innovative antibody-based program for the immunotherapy of type-2 diabetes, and ... Neurimmune - Lab Insights: Immunotherapy for Type-2 diabetes ... http://www.neurimmune.com/stories/lab-insights- immunotherapy-for-type-2-diabetes.html ... Neurimmune - Lab Insights: Immunotherapy for Type-2 diabetes ...
Neurimmune - About Neurimmune
... exclusive rights to three immunotherapy programs with human monoclonal antibodies targeting alpha-synuclein ... executing an agreement granting worldwide exclusive rights to three immunotherapy programs with human ...
Blutspende SRK Zürich
https://www.blutspendezuerich.ch/
8952 Schlieren, Rütistrasse 19
+41 58 272 52 52
info@zhbsd.ch
The Zurich Blood Transfusion Service SRK (ZHBSD) is a nonprofit foundation and independent partner in the healthcare sector. It ensures the supply of blood and blood products to patients in the Zurich region. Our products are made exclusively from voluntary, unpaid blood donations. We offer our services at cost-covering prices and without government subsidies. Along with ten other regional blood donation services in Switzerland, we are a member of the Swiss Red Cross Blood Donation Service (BSD SRK AG).
Blutspende SRK Zürich
Rütistrasse 19
8952 Schlieren
73 Ergebnisse für "immunotherapy com com" unter Blutspende SRK Zürich
Mapping naturally presented T cell antigens in medulloblastoma base...
... cell responses, supporting their potential for T cell immunotherapy. This study is an in-depth mapping ... prerequisite for T cell-based immunotherapy is the pre- sentation of tumor-associated peptides by human ... cell responses, supporting their potential for T cell immunotherapy. This study is an in-depth mapping ... prerequisite for T cell-based immunotherapy is the pre- sentation of tumor-associated peptides by human ...
untitled
... HSCs are com- mitted exclusively to their tissue of origin, namely the hematopoi- etic system. However ... , isolate and culture-expand tu- mor-targeting immune cells. Both basic and clinical research com- munities ... HSCs are com- mitted exclusively to their tissue of origin, namely the hematopoi- etic system. However ... , isolate and culture-expand tu- mor-targeting immune cells. Both basic and clinical research com- munities ...